BioXcel Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-75.33	-69.9	-59.6	-179.05	-165.76	-106.93
Depreciation & Amortization	0.28	0.3	0.31	0.32	0.33	0.3
Stock-Based Compensation	3.02	2.77	6.16	18.61	17.34	19.46
Other Adjustments	13.42	10.92	-12.86	3.1	2.35	0.31
Change in Receivables	-0.22	-0.1	-0.06	0.18	-0.25	-
Changes in Inventories	0.14	-0.04	1.31	-0.01	-1.99	-
Changes in Accounts Payable	11.46	6.97	-4.33	-3.22	13.03	4.85
Changes in Accrued Expenses	-	-	-0.74	2.5	3.8	-
Changes in Other Operating Activities	-10.15	-8.53	-2.22	2.57	-4.2	-0.13
Operating Cash Flow	-57.38	-57.62	-72.03	-155.01	-135.34	-82.15
Capital Expenditures	-	-	-	-0.02	-0.14	-0.45
Investing Cash Flow	-	-	-	-0.02	-0.14	-0.45
Long-Term Debt Issued	-	-	-	-	98.6	-
Long-Term Debt Repaid	-8.11	-	-2.5	-	-	-
Net Long-Term Debt Issued (Repaid)	-8.11	-	-2.5	-	98.6	-
Issuance of Common Stock	52.63	58.14	39.69	27.54	0.28	102.45
Net Common Stock Issued (Repurchased)	52.63	58.14	39.69	27.54	0.28	102.45
Other Financing Activities	-0.98	-1.62	-0.53	-1.02	-2.65	-
Financing Cash Flow	43.55	56.52	36.66	26.52	96.24	102.45
Net Cash Flow	-13.83	-1.1	-35.37	-128.5	-39.24	19.85
Free Cash Flow	-57.38	-57.62	-72.03	-155.03	-135.48	-82.6
FCF Margin	-	-8974.30%	-3178.60%	-11233.80%	-36128.00%	-
Free Cash Flow Per Share	-3.40	-4.72	-28.41	-85.13	-77.38	-50.11
Levered Free Cash Flow	-81.71	-71.2	-67.76	-176.91	-56.32	-102.36
Unlevered Free Cash Flow	-48.86	-51.76	-72.91	-169.64	-148.81	-102.37

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q